江湖电竞直播官方
JAZZ
US
$
0.00
0.00%
After Hours
$
151.55
After Hours Volume:
23.91K
| Close | Chg | Chg % |
|---|---|---|
| $151.55 | -0.45 | -0.30% |
Volume: 491.18K
65 Day Avg: 487.13K
149.38
Day Range
151.88
117.64
52 Week Range
169.98
Overview
JAZZ Overview
Key Data
- Open $151.28
- Day Range 149.38 - 151.88
- 52 Week Range 117.64 - 169.98
- Market Cap $9.53B
- Shares Outstanding 62.68M
- Public Float 60.76M
- Beta 0.78
- Rev. per Employee $1.088M
- P/E Ratio N/A
- EPS -$0.86
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 2.78M 08/15/22
- % of Float Shorted 4.57%
- Average Volume 487.13K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings
18
Full Ratings
Recent News
Jazz Pharmaceuticals started at buy with $194 stock price target at UBS
Jazz, Werewolf sign licensing deal worth up to $1.2 billion
Shares of Werewolf Therapeutics Inc. jumped 10.8% in premarket trading on Thursday after the company announced a licensing deal with Jazz Pharmaceuticals Plc worth up to $1.2 billion. Jazz now has exclusive development a...
Biotech and Pharma Biotech Stocks Could Make a Comeback. The ‘M&A Stars’ Are in Line.
Jazz's leukemia drug gets approved by the FDA
Shares of Jazz Pharmaceuticals plc gained 3.5% in premarket trading on Thursday, the day after the Food and Drug Administration said it had approved the company's acute lymphocytic leukemia treatment Rylaze. The therapy i...
Jazz updates 2021 guidance after closing acquisition of GW Pharmaceuticals
Jazz Pharmaceuticals Plc updated its guidance for 2021 to reflect its acquisition of GW Pharmaceuticals Inc., which closed in early May. Jazz now expects revenue of $3.02 billion to $3.18 billion in 2021, compared with it...
CORRECTED: Jazz Pharmaceuticals now sees 2021 adj. EPS of $13.40 to $14.70 vs prior $15.65 to $16.85
CORRECTED: Jazz Pharmaceuticals now sees 2021 loss per share $4.70 to $2.00 vs. prior guidance for EPS of $8.30 to $1.045
Jazz Pharmaceuticals now sees 2021 revenue of $3.020 bln to $3.180 bln vs. prior $2.550 bln to $2.700 bln
Jazz Pharmaceuticals updates 2021 guidance to include GW Pharma
UPDATE: Jazz Pharmaceuticals to acquire GW Pharma for $7.2 billion in cash and stock, GW soars 46% premarket
Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at $7.2 billion. Under the terms of the deal, Jazz Pharma will pay $200 per share in cash and $20 in...
Axsome (AXSM) up 118.4% in the Past Three Months: Here's Why
Axsome (AXSM) surges in the past three months owing to its Sunosi acquisition and promising progress on its pipeline candidate.
on Zacks.com
Which “Strong Buy” Cannabis Stock Could Offer the Highest Upside Potential?
Cannabis stocks continue to be clobbered this year due to the lack of favorable reforms and the persistent delay in the legalization of cannabis at the federal level. Marijuana continues to be a Schedule 1 substance in the...
on TipRanks.com
Jazz (JAZZ) Up 4% Since Last Earnings Report: Can It Continue?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
on Zacks.com
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate
Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.
on Zacks.com
How Much Upside is Left in Jazz (JAZZ)? Wall Street Analysts Think 29%
The average of price targets set by Wall Street analysts indicates a potential upside of 29.1% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings esti...
on Zacks.com
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
on Zacks.com
2 Top Healthcare Stocks Defying the Bear Market
on Motley Fool
Jazz (JAZZ) Starts Study on Epidiolex for a Fourth Indication
Jazz Pharmaceuticals (JAZZ) initiates a two-part pivotal late-stage study evaluating its epilepsy drug, Epidiolex, in children and adolescents suffering from epilepsy with Myoclonic-Atonic Seizures (EMAS).
on Zacks.com
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
on Benzinga.com
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
on Zacks.com
Wall Street Analysts Predict a 25% Upside in Jazz (JAZZ): Here's What You Should Know
The mean of analysts' price targets for Jazz (JAZZ) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings esti...
on Zacks.com
5 Biotech Stocks in the Buy Zone This Week
on StockNews.com
Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC
Top 5 2nd Quarter Trades of DeepCurrents Investment Group LLC
on GuruFocus.com
Wellesley Asset Management Buys 2, Sells 3 in 2nd Quarter
Wellesley Asset Management Buys 2, Sells 3 in 2nd Quarter
on GuruFocus.com
M.D. SASS INVESTORS SERVICES, INC. Buys 3, Sells 2 in 2nd Quarter
M.D. SASS INVESTORS SERVICES, INC. Buys 3, Sells 2 in 2nd Quarter
on GuruFocus.com
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
on Zacks.com
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
on Zacks.com
Why Axsome Therapeutics Topped the Market Today
on Motley Fool
Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Johnson & Johnson |
|
$431.37B |
| Pfizer Inc. |
|
$258.9B |
| Merck & Co. Inc. |
|
$220.07B |
| Novartis AG |
|
CHF173.37B |
| Bristol Myers Squibb Co. |
|
$146.82B |
| Sanofi S.A. |
|
€101.51B |
| GSK PLC |
|
£54.36B |
| Teva Pharmaceutical Industries Ltd. |
|
₪32.51B |
| Avadel Pharmaceuticals PLC ADR |
|
$352.39M |
| Oncopeptides AB |
|
kr2.75B |